Sign Up Today and Learn More About Ratio Therapeutics Stock
Invest in or calculate the value of your shares in Ratio Therapeutics or other pre-IPO companies through EquityZen's platform.
Ratio Therapeutics Stock (RATT)
Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.
About Ratio Therapeutics Stock
Founded
2021
Headquarters
Boston, MA, US
Industries
Sales and Marketing, Commerce and Shopping, Consumer Goods
Ratio Therapeutics Press Mentions
Stay in the know about the latest news on Ratio Therapeutics
PharmaLogic Announces Successful Supply of First Cohort Dosing for Ratio Therapeutics' Phase 1/2 Study of a Novel FAP-Targeted Radiopharmaceutical in Late-Stage Aggressive Sarcomas
prnewswire • Dec 16, 2025
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
prnewswire • Dec 16, 2025
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
medcitynews • Nov 29, 2025
Chutes & Ladders—Recursion refreshes leadership with CEO swap
fiercebiotech • Nov 09, 2025
Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer
biospace • Nov 05, 2025
Ratio Therapeutics Management
Leadership team at Ratio Therapeutics
Chief Data Officer
Jacob Hesterman
CFO
Reed Malleck
Join now and verify your accreditation status to gain access to:
- Ratio Therapeutics Current Valuation
- Ratio Therapeutics Stock Price
- Ratio Therapeutics Management
- Available deals in Ratio Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ratio Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ratio Therapeutics Revenue and Financials
- Ratio Therapeutics Highlights
- Ratio Therapeutics Business Model
- Ratio Therapeutics Risk Factors
- Ratio Therapeutics Research Report from SACRA Research
Trading Ratio Therapeutics Stock
How to invest in Ratio Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Ratio Therapeutics through EquityZen funds. These investments are made available by existing Ratio Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Ratio Therapeutics stock?
Shareholders can sell their Ratio Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 410K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 50K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
